Laura K Hilton, Henry S Ngu, Brett Collinge, Kostiantyn Dreval, Susana Ben-Neriah, Christopher K Rushton, Jasper C H Wong, Manuela Cruz, Andrew Roth, Merrill Boyle, Barbara Meissner, Graham W Slack, Pedro Farinha, Jeffrey W Craig, Alina S Gerrie, Ciara L Freeman, Diego Villa, Michael Crump, Lois Shepherd, Annette E Hay, John Kuruvilla, Kerry J Savage, Robert Kridel, Aly Karsan, Marco A Marra, Laurie H Sehn, Christian Steidl, Ryan D Morin, David W Scott
Diffuse large B-cell lymphoma (DLBCL) is cured in over 60% of patients, but outcomes are poor for patients with relapsed or refractory disease (rrDLBCL). Here, we performed whole genome/exome sequencing (WGS/WES) on tumors from 73 serially-biopsied patients with rrDLBCL. Based on the observation that outcomes to salvage therapy/autologous stem cell transplantation are related to time-to-relapse, we stratified patients into groups according to relapse timing to explore the relationship to genetic divergence and sensitivity to salvage immunochemotherapy...
March 8, 2023: medRxiv